Endo International plc (ENDP) |
0.2926 0 (0%) 04-04 16:00 |
Open: | 0.3027 |
High: | 0.3059 |
Low: | 0.2805 |
Volume: | 39,155,658 |
Market Cap: | 0(M) |
PE Ratio: | -0.09 |
Exchange: | NASDAQ Global Select |
Industry: | Drug Manufacturers - Specialty & Generic |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 0.31 |
Resistance 1: | 0.30 |
Pivot price: | 0.29 |
Support 1: | 0.28 |
Support 2: | 0.23 |
52w High: | 0.3059 |
52w Low: | 0.2805 |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
EPS | 0.788 |
Book Value | -2.810 |
PEG Ratio | -0.02 |
Gross Profit | 7.618 |
Profit Margin (%) | -24.82 |
Operating Margin (%) | 24.70 |
Return on Assets (ttm) | 5.1 |
Return on Equity (ttm) | 0.0 |
Sun, 21 Apr 2024
Karyopharm Therapeutics (KPTI) in Focus: Stock Goes Down 5.2% - Yahoo Movies Canada
Sun, 21 Apr 2024
Amneal Pharmaceuticals (AMRX) Jumps: Stock Rises 5.6% - Yahoo Movies Canada
Fri, 19 Aug 2022
Endo: End Game And What Burned Investors Can Learn (NASDAQ:ENDP) - Seeking Alpha
Tue, 16 Aug 2022
Endo Creditors Eye Plan for Drugmaker's Sale Through Bankruptcy - Bloomberg
Tue, 09 Aug 2022
Endo International (ENDP) Stock Plunges Amid Bankruptcy Warning - InvestorPlace
Wed, 18 May 2022
Why Shares of Endo International Plummeted 69% on Wednesday - The Motley Fool
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |